Neuromyelitis optica spectrum disorders(NMOSD)are a group of primary central nervous system inflammatory demyelinating diseases mediated by autoimmunity,predominantly affecting the optic nerves and the spinal cord.It commonly occurs in young and middle-aged adults,with a higher prevalence in females.Clinical characteristics include recurrent episodes of optic neuritis and transverse myelitis,leading to a high rate of disability.The activation of the complement system(CS)is a critical step in the onset of NMOSD.Thus,complement inhibitors might emerge as a new treatment strategy for NMOSD.Currently,several complement inhibitors are under clinical trial investigation.This article reviews the recent advancements in the treatment of NMOSD with complement inhibitors.
维普
万方数据